A Phase 3 interventional study of E/C/F/TAF and ABC/3TC in HIV-1 Infection, sponsored by Gilead Sciences. Completed at 49 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-11-14.
Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objective of this study is to evaluate the efficacy of switching to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) fixed-dose combination (FDC) relative to continuing on a baseline regimen consisting of abacavir/lamivudine (ABC/3TC) plus a 3rd antiretroviral agent in HIV-1 infected participants.
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
-infected adult participants who meet the following criteria will be given the option to participate in the study:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will switch to E/C/F/TAF FDC and receive treatment for 48 weeks.
Drug: E/C/F/TAF
Participants will maintain prior regimen of ABC/3TC plus a third antiretroviral agent for 24 weeks followed by a delayed switch to E/C/F/TAF FDC. Note: the prior regimen is determined by the participant's clinician (prior to entry into the study) and will consist of one of the third antiretroviral agents listed.
Drug: ABC/3TC · Drug: Third Antiretroviral Agent
Drug pages: Elvitegravir · Cobicistat · Emtricitabine · Tenofovir alafenamide
150/150/200/10 mg FDC tablets administered orally once daily
Also known as: Genvoya®
600/300 mg tablets administered orally once daily
Also known as: Epzicom, Kivexa
Third antiretroviral agents could include one of the following: * ATV+cobicistat (COBI; Tybost®) or ATV/COBI FDC * DRV+COBI or DRV/COBI FDC * darunavir (DRV; Prezista®) + RTV * lopinavir/ritonavir (LPV/r; Kaletra®) * atazanavir (ATV; Reyataz®) + ritonavir (RTV; Norvir®) * efavirenz (EFV; Sustiva®) * etravirine (ETR; Intelence®) * nevirapine (NVP; Viramune®) * rilpivirine (RPV; Edurant®) * dolutegravir (DTG; Tivicay®) * raltegravir (RAL; Isentress®) * fosamprenavir (FPV; Lexiva®) + RTV * saquinavir (SQV; Invirase®) + RTV * ATV (no booster) Drug classes: * Protease inhibitors (PI): LPV/r, ATV, RTV, ATV, DRV, FPV and SQV * Pharmacokinetic enhancer: COBI * Non-nucleoside reverse transcriptase inhibitors (NNRTI): EFV, RPV, NVP, and ETR * Integrase inhibitors: RAL and DTG
Percentage of Participants Who Have HIV-1 RNA < 50 Copies/mL as Defined by the FDA Snapshot Algorithm at Week 24
The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 24 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
Time frame: Week 24
Percentage of Participants Who Have HIV-1 RNA < 50 Copies/mL as Defined by the FDA Snapshot Algorithm at Week 12
The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at week 12 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
Time frame: Week 12
Percentage of Participants Who Have HIV-1 RNA < 50 Copies/mL as Defined by the FDA Snapshot Algorithm at Week 48
The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
Time frame: Week 48
Change From Baseline in CD4+ Cell Count at Week 24
Time frame: Baseline; Week 24
Change From Baseline in CD4+ Cell Count at Week 48
Time frame: Baseline; Week 48
Participants were enrolled at study sites in Europe and North America. The first participant was screened on 18 November 2015. The last study visit occurred on 24 Jan 2018.
| Milestone | E/C/F/TAF | ABC/3TC+3rd Agent |
|---|---|---|
| Started | 183 | 92 |
| Completed | 171 | 88 |
| Not completed | 12 | 4 |
| Withdrew: Adverse event | 5 | 1 |
| Withdrew: Investigator's discretion | 1 | 0 |
| Withdrew: Non-compliance with study drug | 1 | 0 |
| Withdrew: Withdrew consent | 2 | 2 |
| Withdrew: Lost to follow-up | 3 | 0 |
| Withdrew: Randomized but not treated | 0 | 1 |
The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 24 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
| percentage of participants | E/C/F/TAF | ABC/3TC+3rd Agent | Delayed E/C/F/TAF |
|---|---|---|---|
| Percentage of Participants Who Have HIV-1 RNA < 50 Copies/mL as Defined by the FDA Snapshot Algorithm at Week 24 | 93.4 | 97.8 | 96.6 |
The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at week 12 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
| percentage of participants | E/C/F/TAF | ABC/3TC+3rd Agent | Delayed E/C/F/TAF |
|---|---|---|---|
| Percentage of Participants Who Have HIV-1 RNA < 50 Copies/mL as Defined by the FDA Snapshot Algorithm at Week 12 | 95.1 | 98.9 | 96.6 |
The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
| percentage of participants | E/C/F/TAF |
|---|---|
| Percentage of Participants Who Have HIV-1 RNA < 50 Copies/mL as Defined by the FDA Snapshot Algorithm at Week 48 | 86.9 |
| cells/µL | E/C/F/TAF | ABC/3TC+3rd Agent | Delayed E/C/F/TAF |
|---|---|---|---|
| Change From Baseline in CD4+ Cell Count at Week 24 | -28 ± 161.4 | 8 ± 192.9 | -23 ± 201.7 |
| cells/µL | E/C/F/TAF |
|---|---|
| Change From Baseline in CD4+ Cell Count at Week 48 | -32 ± 147.1 |
Collected over Up to 48 weeks plus 30 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| E/C/F/TAF | 0/183 (0%) | 12/183 (6.6%) | 71/183 (38.8%) |
| ABC/3TC+3rd Agent | 0/91 (0%) | 1/91 (1.1%) | 21/91 (23.1%) |
| Delayed E/C/F/TAF | 0/89 (0%) | 4/89 (4.5%) | 17/89 (19.1%) |
| All E/C/F/TAF | 0/272 (0%) | 16/272 (5.9%) | 88/272 (32.4%) |
| Event | E/C/F/TAF | ABC/3TC+3rd Agent | Delayed E/C/F/TAF | All E/C/F/TAF |
|---|---|---|---|---|
| ErysipelasInfections and infestations | 0/183 | 0/91 | 1/89 | 1/272 |
| Respiratory tract infectionInfections and infestations | 0/183 | 0/91 | 1/89 | 1/272 |
| Urinary tract infectionInfections and infestations | 1/183 | 0/91 | 1/89 | 2/272 |
| Cervical dysplasiaReproductive system and breast disorders | 0/183 | 0/91 | 1/89 | 1/272 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/183 | 0/91 | 1/89 | 1/272 |
| Deep vein thrombosisVascular disorders | 0/183 | 0/91 | 1/89 | 1/272 |
| Small intestinal obstructionGastrointestinal disorders | 0/183 | 1/91 | 0/89 | 0/272 |
| PneumoniaInfections and infestations | 2/183 | 0/91 | 0/89 | 2/272 |
| Coronary artery diseaseCardiac disorders | 1/183 | 0/91 | 0/89 | 1/272 |
| Myocardial infarctionCardiac disorders | 1/183 | 0/91 | 0/89 | 1/272 |
| Event | E/C/F/TAF | ABC/3TC+3rd Agent | Delayed E/C/F/TAF | All E/C/F/TAF |
|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 19/183 | 3/91 | 4/89 | 23/272 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 11/183 | 2/91 | 8/89 | 19/272 |
| HeadacheNervous system disorders | 15/183 | 4/91 | 4/89 | 19/272 |
| Vitamin D deficiencyMetabolism and nutrition disorders | 13/183 | 6/91 | 0/89 | 13/272 |
| Back painMusculoskeletal and connective tissue disorders | 6/183 | 6/91 | 2/89 | 8/272 |
| Upper respiratory tract infectionInfections and infestations | 12/183 | 5/91 | 1/89 | 13/272 |
| AstheniaGeneral disorders | 10/183 | 1/91 | 0/89 | 10/272 |
Safety Analysis Set: participants who took at least 1 dose of E/C/F/TAF or ABC/3TC+3rd Agent (on or after Day 1).
| Age, Continuous(years) | E/C/F/TAF | ABC/3TC+3rd Agent | Total |
|---|---|---|---|
| Mean | 50 ± 11.6 | 49 ± 10.7 | 49 ± 11.3 |
| Sex: Female, Male(Participants) | E/C/F/TAF | ABC/3TC+3rd Agent | Total |
|---|---|---|---|
| Female | 27 | 17 | 44 |
| Male | 156 | 74 | 230 |
| Race/Ethnicity, Customized(Participants) | E/C/F/TAF | ABC/3TC+3rd Agent | Total |
|---|---|---|---|
| Asian | 5 | 1 | 6 |
| Black | 27 | 15 | 42 |
| White | 150 | 75 | 225 |
| Other | 1 | 0 | 1 |
| Race/Ethnicity, Customized(Participants) | E/C/F/TAF | ABC/3TC+3rd Agent | Total |
|---|---|---|---|
| Hispanic or Latino | 27 | 16 | 43 |
| Not Hispanic or Latino | 155 | 73 | 228 |
| Not Permitted | 1 | 2 | 3 |
| Region of Enrollment(Participants) | E/C/F/TAF | ABC/3TC+3rd Agent | Total |
|---|---|---|---|
| United States | 36 | 19 | 55 |
| Italy | 43 | 16 | 59 |
| United Kingdom | 2 | 1 | 3 |
| France | 40 | 23 | 63 |
| Germany | 6 | 2 | 8 |
| Spain | 56 | 30 | 86 |
| HIV-1 RNA Categories(Participants) | E/C/F/TAF | ABC/3TC+3rd Agent | Total |
|---|---|---|---|
| < 50 copies/mL | 177 | 91 | 268 |
| 50 ≥ copies/mL | 6 | 0 | 6 |
| CD4 Cell Count(cells/µL) | E/C/F/TAF | ABC/3TC+3rd Agent | Total |
|---|---|---|---|
| Mean | 701 ± 280.1 | 753 ± 312.8 | 718 ± 291.8 |
| CD4 Cell Count Category(Participants) | E/C/F/TAF | ABC/3TC+3rd Agent | Total |
|---|---|---|---|
| ≥ 50 to < 200 cells/µL | 2 | 0 | 2 |
| ≥ 200 to < 350 cells/µL | 11 | 7 | 18 |
| ≥ 350 to < 500 cells/µL | 30 | 13 | 43 |
| ≥ 500 cells/µL | 140 | 71 | 211 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at http://www.gilead.com/research/disclosure-and-transparency.
Supporting information: Study protocol, Statistical analysis plan
Time frame: 18 months after study completion
Access criteria: A secured external environment with username, password, and RSA code.
Data sharing details ↗ · www.gilead.com
Ran from Nov 2015 to primary completion in Jun 2017, 18 months.
Results were first posted in Jul 2018, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Elvitegravir · Cobicistat · Emtricitabine · Tenofovir alafenamide